enGene Therapeutics (ENGN) Accumulated Depreciation (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Accumulated Depreciation of $2.5 million for Q2 2026, up 35.04% year-over-year from $1.8 million in Q2 2025, and up 7.11% quarter-over-quarter from $2.3 million in Q1 2026.
enGene Therapeutics (ENGN) Accumulated Depreciation (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Accumulated Depreciation for 5 consecutive years, with $2.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Accumulated Depreciation rose 35.04% year-over-year to $2.5 million; the TTM figure through Apr 2026 stood at $2.5 million (up 35.04% YoY), while the FY2025 annual figure was $2.1 million, up 30.62% from the prior year.
- Accumulated Depreciation grew to $2.5 million in Q2 2026 per ENGN's latest filing, from $2.3 million in the prior quarter.
- Across five years, Accumulated Depreciation topped out at $2.5 million in Q2 2026 and bottomed at $1.5 million in Q3 2024.
- Historically, Accumulated Depreciation has averaged $1.9 million across 5 years, with a median of $1.8 million in 2024.
- Annual changes were most pronounced in 2024 — Accumulated Depreciation dropped 6.77% — and 2026, when it soared 35.04%.
- enGene Therapeutics' Accumulated Depreciation stood at $1.6 million in 2022, then rose by 11.2% to $1.7 million in 2023, then dropped by 6.77% to $1.6 million in 2024, then soared by 30.62% to $2.1 million in 2025, then rose by 16.74% to $2.5 million in 2026.
- Business Quant data shows ENGN's Accumulated Depreciation at $2.5 million in Q2 2026, $2.3 million in Q1 2026, and $2.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 2.46 Mn |
| Jan 31, 2026 | 2.29 Mn |
| Oct 31, 2025 | 2.10 Mn |
| Jul 31, 2025 | 1.93 Mn |
| Apr 30, 2025 | 1.82 Mn |
| Jan 31, 2025 | 1.71 Mn |
| Oct 31, 2024 | 1.61 Mn |
| Jul 31, 2024 | 1.53 Mn |
| Apr 30, 2024 | 1.89 Mn |
| Jan 31, 2024 | 1.81 Mn |
| Oct 31, 2023 | 1.73 Mn |
| Oct 31, 2022 | 1.55 Mn |